UltraTech Cement Q3 Results: Profit drops by 16.98% to Rs 1,473.51 crore, beats estimates

Cement major UltraTech Cement, an Aditya Birla Group company, on Thursday reported a profit of Rs 1,473.51 crore for the fiscal third quarter, posting a drop of 16.98 per cent in comparison to Rs 1,774.78 crore during the corresponding quarter of FY24, surpassing estimates. It recorded revenue from operations at Rs 17,193.33 crore, up 2.71 per cent as against Rs 16,739.97 crore during the third quarter of previous financial year. The company EBITDA stood at Rs 2,887 crore. According to a CNBC TV18 poll, Ultratech Cement was expected to post profit for the third quarter of FY25 at Rs 1,295 crore and revenue for the period was estimated at Rs 17,025 crore. 

During the quarter, UltraTech achieved a capacity utilisation of 73 per cent. Domestic sales volume, meanwhile, grew by 10 per cent YoY. It said that energy costs were lower by 13 per cent YoY and 4 per cent QoQ during the period, mainly on account of decrease in fuel cost.

Also ReadRestaurant industry flags Zomato, Swiggy’s private labels as unfair competition

As part of its ongoing capacity expansion program, UltraTech said, it commissioned an additional 1.8 mtpa capacity. Further, with the acquisition of The India Cements Limited, UltraTech’s cement capacity has increased to 171.11 mtpa, on a consolidated basis. Upon completion of the ongoing expansion projects and the acquisition of Kesoram Cement (10.75 MTPA), UltraTech will achieve the unique milestone of more than 200 mtpa cement capacity in the country by the end of FY27.

Transaction Update

In a regulatory filing, UltraTech said that upon receiving an unconditional approval from the Competition Commission of India, the company acquired 10,13,91,231 equity shares of Rs 10 each of The India Cements Limited (ICEM), representing 32.72 per cent of ICEM’s equity share capital, from the former promoters and one other shareholder. “With this acquisition, along with its existing shareholding of 22.77 per cent, UltraTech’s total shareholding in ICEM has increased to 17,19,55,887 equity shares, representing 55.49 per cent of ICEM’s equity share capital. As a result, ICEM has become a subsidiary of UltraTech, effective 24th December, 2024,” it said. Additionally, UltraTech has also made an open offer to the public shareholders of ICEM to acquire upto 8,05,73,273 equity shares of Rs 10 each, representing 26 per cent of ICEM’s equity share capital,

 » Read More

Related Articles

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

Good news for taxpayers! Govt removes THESE difficulties to ensure more tax cases are settled – Check details!

Good news for taxpayers! The Finance Ministry has made some changes to the Direct Tax Vivad Se Vishwas Scheme, 2024, removing “difficulties” that arose due to certain situations for taxpayers. This update in the scheme will bring relief to taxpayers who wanted to apply for the scheme but could not do so earlier. “CBDT…makes the

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

Good news for taxpayers! Govt removes THESE difficulties to ensure more tax cases are settled – Check details!

Good news for taxpayers! The Finance Ministry has made some changes to the Direct Tax Vivad Se Vishwas Scheme, 2024, removing “difficulties” that arose due to certain situations for taxpayers. This update in the scheme will bring relief to taxpayers who wanted to apply for the scheme but could not do so earlier. “CBDT…makes the

Johnnie Walker-maker United Spirits posts Q3 profit decline of 4.29% to Rs 335 crore, revenue up 11.06% YoY

United Spirits, which makes Smirnoff vodka, on Thursday reported a profit of Rs 335 crore for the third quarter of FY25, posting a decline of 4.29 per cent in comparison to Rs 350 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 7,732 crore, reporting a growth of

Q3FY25: Mankind Pharma’s revenue up by 24 percent to Rs 3,230 Crore; Profit at Rs 380 crore

Pharma major Mankind Pharma on Thursday reported its financial results for the third quarter and nine months ended 31 st December 2024. The company reported revenue from Operations at Rs. 3,230 Cr, up by 24% YoY and domestic revenue at INR 2,773 Cr, up 17%, Exports at INR 457 Cr, up 121% YoY. The company’s